333
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Long-term follow-up of HIV seroconverters in microbicide trials – rationale, study design, and challenges in MTN-015

, , , , , , , , , , , , & show all

References

  • Etter P, Landovitz R, Sibeko S, et al. Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. AIDS. 2013;27(7):1119–1128.10.1097/QAD.0b013e32835dc08e
  • Garrett NJ, Werner L, Naicker N, et al. HIV disease progression in seroconvertors from the CAPRISA 004 Tenofovir gel pre-exposure prophylaxis trial. J Acquir Immune Defic Syndr. 2015;68(1):55–61.10.1097/QAI.0000000000000367
  • Kersh EN, Luo W, Zheng Q, et al. Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis. J Infect Dis. 2012;206(5):770–779.10.1093/infdis/jis422
  • Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.10.1056/NEJMoa1108524
  • Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599.10.1056/NEJMoa1011205
  • Grant RM, Liegler T, Defechereux P, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29(3):331–337.10.1097/QAD.0000000000000556
  • Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014;210(8):1217–1227.10.1093/infdis/jiu233
  • Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–434.10.1056/NEJMoa1110711
  • Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–518.10.1056/NEJMoa1402269
  • Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–1174.10.1126/science.1193748
  • Wei X, Hunt G, Abdool Karim SS, et al. Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. J Infect Dis. 2014;209(12):1916–1920.10.1093/infdis/jiu026
  • Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957–966.10.1097/QAD.0b013e32834541d9
  • Penrose KJ, Parikh UM, Hamanishi KA, et al. Selection of Rilpivirine-resistant HIV-1 in a seroconverter from the SSAT 040 trial who received the 300-mg dose of long-acting Rilpivirine (TMC278LA). J Infect. Dis. 2016;213:1013–1017.
  • Hesbacher PT, Rickels K, Morris RJ, et al. Psychiatric illness in family practice. J Clin Psychiatry. 1980;41(1):6–10.
  • Kaaya SF, Fawzi MC, Mbwambo JK, et al. Validity of the Hopkins symptom checklist-25 amongst HIV-positive pregnant women in Tanzania. Acta Psychiatr Scand. 2002;106(1):9–19.
  • World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children; 2007. Available from: www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf
  • Palanee-Phillips T, Schwartz K, Brown ER, et al. Characteristics of women enrolled into a randomized clinical trial of dapivirine vaginal ring for HIV-1 prevention. PLos One. 2015;10(6):e0128857.10.1371/journal.pone.0128857
  • Naik R, Doherty T, Jackson D, et al. Linkage to care following a home-based HIV counselling and testing intervention in rural South Africa. J Int AIDS Soc. 2015;18:19843.
  • Turan B, Stringer KL, Onono M, et al. Linkage to HIV care, postpartum depression, and HIV-related stigma in newly diagnosed pregnant women living with HIV in Kenya: a longitudinal observational study. BMC Pregnancy Childbirth. 2014;14:1–10.10.1186/s12884-014-0400-4
  • McKenney JL. Behavior change and other factors related to HIV transmission among female sero-converters in microbicide trials. Epidemiology, University of California Los Angeles; 2015. Available from: http://escholarship.org/uc/item/7kj8z5wc
  • Antelman G, Kaaya S, Wei R, et al. Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. J Acquir Immune Defic Syndr. 2007;44(4):470–477.10.1097/QAI.0b013e31802f1318
  • Gorbach PM, Mensch BS, Husnik M, et al. Effect of computer-assisted interviewing on self-reported sexual behavior data in a microbicide clinical trial. AIDS Behav. 2013;17(2):790–800.10.1007/s10461-012-0302-2

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.